New drug BL-B01D1 enters human trials for Hard-to-Treat cancers
NCT ID NCT05194982
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called BL-B01D1 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find a safe dose, and second, to check how well that dose works and how the body handles it. About 570 participants will take part to help determine if this drug is worth studying further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the drug will be effective. Side effects are possible and will be closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, China
Contact
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, China
Contact
-
Renmin Hospital of Wuhan University
RECRUITINGWuhan, Hubei, China
Contact
-
Shanghai Oriental Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Shanxi Cancer Hospital
RECRUITINGTaiyuan, Shanxi, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, China
Contact
-
Union Hospital Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact